Skip to content

Chinese Biotech I-Mab Weighing Options Including Sale

  • Other global drugmakers showed interest in acquiring I-Mab
  • Options also include a merger with another firm or partnership
Updated on

Chinese biotechnology firm I-Mab is exploring options including a sale of the business amid takeover interest from other global drugmakers, according to people familiar with the matter.

The Nasdaq-traded company is working with advisers on a strategic review after drawing interest from U.S. and European pharmaceutical giants seeking to expand in cancer therapies in the world’s second-largest economy, the people said.